Read by QxMD icon Read

"club rhumatisme"

Valérie Devauchelle-Pensec, Lea Saraux, Jean Marie Berthelot, Michel De Bandt, Divi Cornec, Dewi Guellec, Thierry Marhadour, Sandrine Jousse-Joulin, Maelenn Gouillou, Alain Saraux
Objective: The PMR activity score (PMR-AS) includes the CRP value, which may be lacking or invalid owing to anti-IL-6 therapy. Our objective was to develop alternatives to PMR-AS that do not require CRP. Methods: We used the Club Rhumatisme et Inflammation (CRI; 89 patients with PMR) and the Tolerance and Efficacy of tocilizumab iN pOlymyalgia Rheumatica (TENOR; 20 patients with recent-onset PMR naive to glucocorticoid who received three tocilizumab infusions, at weeks 0, 4 and 8, followed by prednisone from weeks 12 to 24) cohorts...
April 1, 2018: Rheumatology
Elodie Rivière, Laurent Arnaud, Mikael Ebbo, Yannick Allanore, Pascal Claudepierre, Emmanuelle Dernis, Jean-Marc Ziza, Corinne Miceli-Richard, Peggy Philippe, Christophe Richez, Martin Soubrier, Rakiba Belkhir, Raphaèle Seror, Xavier Mariette, Stephan Pavy
OBJECTIVE: Spondyloarthritis (SpA) and Takayasu arteritis (TA) are 2 chronic inflammatory diseases; their coexistence in a single patient is uncommon. The aims of our study were to describe clinical features of patients having SpA associated with TA and to identify some characteristics of the types of patients with SpA associated with TA. We also analyzed treatments used in this context. METHODS: This French multicenter retrospective survey called for observations on behalf of the Club Rhumatismes et Inflammations, with a standardized questionnaire established by the investigators...
July 2017: Journal of Rheumatology
Morgane Beck, Bruno Michel, Marie-Christine Rybarczyk-Vigouret, Dominique Levêque, Christelle Sordet, Jean Sibilia, Michel Velten
BACKGROUND: Healthcare cost savings are closely linked to prescribers' confidence in and acceptance of the prescription of biosimilar drugs. OBJECTIVES: The aim of this study was to assess the knowledge, experience and opinions of hospital-based and office-based French rheumatologists with regard to biosimilar medicines and to identify the barriers to and possible options to promote their prescription. METHODS: A web-based, self-administered survey was conducted among French rheumatologists from June 8 to August 2, 2015...
December 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Alexis Régent, Serge Redeker, Alban Deroux, Pierre Kieffer, Kim Heang Ly, Maxime Dougados, Eric Liozon, Claire Larroche, Loïc Guillevin, Laurence Bouillet, Olivier Espitia, Nathalie Costedoat-Chalumeau, Martin Soubrier, Benoît Brihaye, François Lifermann, Guillaume Lefevre, Xavier Puéchal, Luc Mouthon, Eric Toussirot
OBJECTIVE: To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA). METHODS: A retrospective multicenter study that included 34 patients receiving TCZ for GCA. RESULTS: TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3...
August 2016: Journal of Rheumatology
F Danion, N Rosine, R Belkhir, J E Gottenberg, E Hachulla, E Chatelus, G Pugnet, Y M Pers, X Mariette, J Sibilia, R Seror
Objective The objective of this study was to assess the safety and efficacy of abatacept in patients with SLE refractory to conventional treatment in routine clinical practice. Methods This retrospective study included 11 SLE patients treated with abatacept for an active and refractory disease. The primary endpoint was the change in SLE Disease Activity Index (SLEDAI) score at six months. Response was defined as a decrease of SLEDAI ≥4 in a patient continuing abatacept. Results Indications of abatacept treatment were articular ( n=8), renal ( n=1) and cutaneous ( n=1) involvement and autoimmune thrombocytopenia ( n=1)...
November 2016: Lupus
G Nocturne, A Virone, Wan-Fai Ng, V Le Guern, E Hachulla, D Cornec, C Daien, O Vittecoq, B Bienvenu, C Marcelli, D Wendling, Z Amoura, R Dhote, C Lavigne, R Fior, J E Gottenberg, R Seror, X Mariette
OBJECTIVE: To define parameters predictive of lymphoma development in patients with primary Sjögren's syndrome (SS). METHODS: A multicenter case-control survey was performed to identify predictors of lymphoma. Cases were patients who developed lymphoma after diagnosis of primary SS and were mainly recruited through the Club Rhumatismes et Inflammation network. For each case, 2 controls (matched for disease duration and age) were randomly selected among patients with primary SS and without lymphoma...
April 2016: Arthritis & Rheumatology
Alain Meyer, Guillaume Lefevre, Guillaume Bierry, Aurélie Duval, Sébastien Ottaviani, Olivier Meyer, Anne Tournadre, Benoit Le Goff, Laurent Messer, Anne Laure Buchdahl, Michel De Bandt, Christophe Deligny, Matthieu Dubois, Pascal Coquerelle, Géraldine Falgarone, René-Marc Flipo, Alexis Mathian, Bernard Geny, Zahir Amoura, Olivier Benveniste, Eric Hachulla, Jean Sibilia, Baptiste Hervier
Anticitrullinated peptide/protein antibodies (ACPA), which are highly specific for rheumatoid arthritis (RA), may be found in some patients with other systemic autoimmune diseases. The clinical significance of ACPA in patients with antisynthetase syndrome (ASS), a systemic disease characterized by the association of myositis, interstitial lung disease, polyarthralgia, and/or polyarthritis, has not yet been evaluated with regard to phenotype, prognosis, and response to treatment. ACPA-positive ASS patients were first identified among a French multicenter registry of patients with ASS...
May 2015: Medicine (Baltimore)
Manuelle Viguier, Stéphanie Rist, François Aubin, Marie-Thérèse Leccia, Marie-Aleth Richard, Marina Esposito-Farèse, Philippe Gaudin, Thao Pham, Pascal Richette, Daniel Wendling, Jean Sibilia, Florence Tubach
Patients with inflammatory rheumatisms, such as rheumatoid arthritis, are more prone to develop skin cancers than the general population, with an additional increased incidence when receiving TNF blockers. There is therefore a need that physicians treating patients affected with inflammatory rheumatisms with TNF blockers recognize malignant skin lesions, requiring an urgent referral to the dermatologist and a potential withdrawal or modification of the immunomodulatory treatment. We aimed to demonstrate that an online training dedicated to skin tumors increase the abilities of rheumatologists to discriminate skin cancers from benign skin tumors...
2015: PloS One
Dewi Guellec, Emilie Cornec-Le Gall, Matthieu Groh, Eric Hachulla, Alexandre Karras, Pierre Charles, Bertrand Dunogué, Sébastien Abad, Fernand Alvarez, Fréderic Gérard, Valérie Devauchelle-Pensec, Jacques-Olivier Pers, Xavier Puéchal, Loïc Guillevin, Alain Saraux, Divi Cornec
OBJECTIVES: To describe the clinical presentation, management and prognosis of patients diagnosed with both primary Sjögren's syndrome (pSS) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). METHODS: French nation-wide survey completed by a systematic literature review. RESULTS: This work identified 7 new cases of coexisting pSS and AAV: 2 microscopic polyangiitis (MPA), 2 granulomatosis with polyangiitis (GPA), 2 anti-myeloperoxidase (MPO)-ANCA renal-limited AAV, and 1 eosinophilic granulomatosis with polyangiitis (EGPA)...
August 2015: Autoimmunity Reviews
Hélène Bauer, Cécile Luxembourger, Jacques-Eric Gottenberg, Sophie Fournier, Florence Abravanel, Alain Cantagrel, Emmanuel Chatelus, Pascal Claudepierre, Christophe Hudry, Jacques Izopet, Sylvie Fabre, Guillaume Lefevre, Laurent Marguerie, Antoine Martin, Laurent Messer, Anna Molto, Béatrice Pallot-Prades, Yves-Marie Pers, Anne-Marie Roque-Afonso, Christian Roux, Christelle Sordet, Martin Soubrier, Claire Veissier, Daniel Wendling, Jean-Marie Péron, Jean Sibilia
The clinical presentation and outcome of hepatitis E virus (HEV) infection in inflammatory rheumatic diseases are unknown. We aimed to investigate the severity of acute HEV infection and the risk of chronic viral replication in patients with inflammatory arthritides treated with immunosuppressive drugs. All rheumatology and internal medicine practitioners belonging to the Club Rhumatismes et Inflammation in France were sent newsletters asking for reports of HEV infection and inflammatory arthritides. Baseline characteristics of patients and the course of HEV infection were retrospectively assessed by use of a standardized questionnaire...
April 2015: Medicine (Baltimore)
Linda Rossi-Semerano, Bruno Fautrel, Daniel Wendling, Eric Hachulla, Caroline Galeotti, Luca Semerano, Isabelle Touitou, Isabelle Koné-Paut
BACKGROUND: Despite their limited licensed indications, anti-interleukin-1 (anti-IL-1) agents are often used in clinical practice for an increasing number of auto-inflammatory diseases. We conducted a national cross-sectional observational study from January 2011 to January 2013 to record the off-label use of such agents in France. We aimed to estimate the off-label use of anti-IL-1 treatments in France, assess their efficacy in rare diseases, and increase the reporting of their possible side effects...
February 15, 2015: Orphanet Journal of Rare Diseases
Alice Courties, Gilles Grateau, Peggy Philippe, René-Marc Flipo, Leonardo Astudillo, Bérengère Aubry-Rozier, Isabelle Fabreguet, Wafki Fahd, Olivier Fain, Pascal Guggenbuhl, Eric Hachulla, Thomas Papo, Christophe Richez, Jean Sibilia, Jacques Morel, Francis Berenbaum, Jérémie Sellam
BACKGROUND: In published case reports, tocilizumab (TCZ) has shown good efficacy for AA amyloidosis in almost all patients. We investigated the efficacy and safety of TCZ in AA amyloidosis in a multicentre study of unselected cases. METHODS: We e-mailed rheumatology and internal medicine departments in France, Switzerland and North Africa by using the Club Rhumatismes Inflammation (CRI) network and the French TCZ registry, Registry RoAcTEmra (REGATE), to gather data on consecutive patients with histologically proven AA amyloidosis who had received at least one TCZ infusion...
2015: Amyloid: the International Journal of Experimental and Clinical Investigation
Guillaume Lefèvre, Alain Meyer, David Launay, Irène Machelart, Michel DeBandt, Julien Michaud, Anne Tournadre, Pascal Godmer, Jean-Emmanuel Kahn, Aurélie Behra-Marsac, Marie-Agnès Timsit, Nicolas Schleinitz, Daniel Wendling, Sylvie Melac-Ducamp, Philippe Boyer, Anne Peretz, Thierry Lequerré, Christophe Richez, Lidwine Stervinou-Wemeau, Sandrine Morell-Dubois, Marc Lambert, Sylvain Dubucquoi, Benoit Wallaert, Olivier Benveniste, René-Marc Flipo, Pierre-Yves Hatron, Jean Sibilia, Eric Hachulla, Baptiste Hervier
OBJECTIVE: The aim of this study was to determine the frequency and characteristics of antisynthetase syndrome (ASS) revealed by polyarthritis. METHODS: First we conducted a retrospective single-centre study to assess the frequency of ASS patients who presented with polyarthritis without pulmonary and/or muscle symptoms. Secondly, we conducted a larger, multicentre study in order to describe the clinical characteristics of these patients. Exclusion criteria were the presence of RF, the presence of ACPA and overlap with another CTD...
May 2015: Rheumatology
Marion Couderc, Jacques-Eric Gottenberg, Xavier Mariette, Bruno Pereira, Thomas Bardin, Alain Cantagrel, Bernard Combe, Maxime Dougados, René-Marc Flipo, Xavier Le Loët, Thierry Shaeverbeke, Philippe Ravaud, Martin Soubrier
OBJECTIVE: The response rate to many therapies for RA is lower in women. The aim of this study was to analyse the influence of gender on the response to rituximab (RTX) in patients with RA. METHODS: A total of 1709 RA patients were included in the French Autoimmunity and Rituximab (AIR) registry. Disease activity assessed by the 28-joint DAS (DAS28) was recorded at baseline and at follow-up (6, 12, 18 and 24 months). Response criteria [European League Against Rheumatism (EULAR) remission defined as a DAS28 < 2...
October 2014: Rheumatology
Séverine Guillaume-Czitrom
No abstract text is available yet for this article.
February 2014: Joint, Bone, Spine: Revue du Rhumatisme
Arsène Mekinian, Thorsten Braun, Olivier Decaux, Géraldine Falgarone, Eric Toussirot, Loic Raffray, Mohamed Omouri, Bruno Gombert, Benoit De Wazieres, Anne-Laure Buchdaul, Jean-Marc Ziza, David Launay, Guillaume Denis, Serge Madaule, Christian Rose, Eric Grignano, Pierre Fenaux, Olivier Fain
We describe the characteristics and outcome of inflammatory arthritis in patients with myelodysplastic syndrome (MDS) in a French multicenter retrospective study. Twenty-two patients with MDS (median age, 77.5 yr [interquartile range, 69-81]; 10 women) were included. Inflammatory arthritis presented as polyarthritis in 17 cases (77%) and with symmetric involvement in 15 cases (68%). At diagnosis, the median disease activity score 28 based on C-reactive protein (DAS28-CRP) was 4.5 [2-6.5]. Two patients had anti-citrullinated protein antibodies (ACPAs), and 1 had radiologic erosions...
January 2014: Medicine (Baltimore)
Vincent Goëb, Marc Ardizzone, Laurent Arnaud, Jérôme Avouac, Athan Baillet, Alexandre Belot, Béatrice Bouvard, Pascal Coquerelle, Sabrina Dadoun, Alain Diguet, David Launay, Danielle Lebouc, Pierre Loulergue, Sophie Mahy, Pascal Mestat, Gaël Mouterde, Benjamin Terrier, Coralie Varoquier, Mathieu Verdet, Xavier Puéchal, Jean Sibilia
The use of TNFα antagonists must follow specific guidelines to ensure optimal effectiveness and safety. The French Society for Rheumatology (SFR) and Task Force on Inflammatory Joint Diseases (CRI), in partnership with several French learned societies, asked the French National Authority for Health (HAS) to develop and endorse good practice guidelines for the prescription and monitoring of TNFα antagonist therapy by physicians belonging to various specialties. These guidelines were developed, then, validated by two multidisciplinary panels of experts based on an exhaustive review of the recent literature and in compliance with the methodological rules set forth by the HAS...
December 2013: Joint, Bone, Spine: Revue du Rhumatisme
Noémie Abisror, Arsene Mekinian, Christian Lavigne, Marie-Anne Vandenhende, Michael Soussan, Olivier Fain
BACKGROUND/PURPOSE: The aim of this study is to analyze the efficacy and tolerance of tocilizumab in patients with Takayasu arteritis (TA). METHODS: We retrospectively studied patients with TA (ACR and/or Ishikawa's criteria): 5 French multicenter cases and 39 from the literature. Clinical, biological, radiological disease activity and treatment were analyzed before tocilizumab, during the follow-up and at the last available visit. RESULTS: Forty-four patients (median age 26years [3-65];) were included in the present study: 5 patients from the 3 French university hospitals and 39 cases from the literature review...
October 2013: Autoimmunity Reviews
Raphaèle Seror, Christophe Richez, Christelle Sordet, Stéphanie Rist, Laure Gossec, Guillaume Direz, Eric Houvenagel, Jean-Marie Berthelot, Christian Pagnoux, Emmanuelle Dernis, Sylvie Melac-Ducamp, Beatrice Bouvard, Caroline Asquier, Antoine Martin, Xavier Puechal, Xavier Mariette
OBJECTIVE: To determine the pattern of demyelinating disorders (DDs) occurring during anti-TNF-α therapy. METHODS: Between June 2005 and April 2008, 1800 French rheumatologists and internists were contacted to report cases of DDs occurring in patients treated with anti-TNF-α. RESULTS: After a median of 10.2 (1.5-39.9) months of treatment, 33 patients developed DDs: 22 had CNS and 11 peripheral nervous system (PNS) involvement. Underlying diseases were RA (n = 16), AS (n = 11), PsA (n = 4), JIA (n = 1) and PM (n = 1)...
May 2013: Rheumatology
Jacques-Eric Gottenberg, Gael Cinquetti, Claire Larroche, Bernard Combe, Eric Hachulla, Olivier Meyer, Edouard Pertuiset, Guy Kaplanski, Laurent Chiche, Jean-Marie Berthelot, Bruno Gombert, Philippe Goupille, Christian Marcelli, Séverine Feuillet, Jean Leone, Jean Sibilia, Charles Zarnitsky, Philippe Carli, Stephanie Rist, Philippe Gaudin, Carine Salliot, Muriel Piperno, Adeline Deplas, Maxime Breban, Thierry Lequerre, Pascal Richette, Charles Ghiringhelli, Mohamed Hamidou, Philippe Ravaud, Xavier Mariette
OBJECTIVES: To evaluate the efficacy and safety of rituximab in patients with primary Sjögren's syndrome (pSS). METHODS: The AutoImmune and Rituximab registry has included 86 patients with pSS treated with rituximab, prospectivey followed up every 6 months for 5 years. RESULTS: Seventy-eight patients with pSS (11 men, 67 women), who already had at least one follow-up visit, were analysed. Median age was 59.8 years (29-83), median duration of disease was 11...
June 2013: Annals of the Rheumatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"